|
|
Article: Labopharm Receives Second Approvable Letter from FDA for Once-Daily Tramadol.
- Article from:
- PR Newswire
- Article date:
- May 31, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LAVAL, QC, May 31 /PRNewswire-FirstCall/ -- Labopharm Inc. (TSX: DDS, NASDAQ: DDSS) today announced that it has received a second approvable letter from the U.S. Food and Drug Administration (FDA) for its once-daily formulation of tramadol.
In the second approvable letter (dated May 30, 2007), the FDA stated that Labopharm has not demonstrated the efficacy of its once-daily formulation of tramadol because the statistical methods used to analyze data from Labopharm's clinical trials did not adequately address missing data relating to subjects who dropped out of the trials. The FDA did not provide guidance with respect to how the statistical methods were not ...